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ABSTRACT 
A PILOT STUDY OF PROPOFOL AS AN ANTI-EMETIC IN LAPAROSCOPIC, 
GYNECOLOGIC SURGERY PATIENTS 
by Flem-Flam Aaron Flemister 
December 2015 
The goal of this project was to use sub-hypnotic doses of propofol to decrease 
postoperative nausea and vomiting (PONV) rates in the immediate post-operative period 
in females, ages 18-65, undergoing laparoscopic gynecologic surgery. 
PONV is one of the largest complications of anesthesia affecting 20-30% of all 
surgical patients.  Risk factors associated with PONV are female gender, laparoscopy, 
general anesthesia, opioids, volatile agents, and post-operative pain; all of which are 
frequently encountered.  The incidence of PONV can prolong recovery time, delay 
discharge, increase patient cost, decrease patient satisfaction, and can cause significant 
medical complications.  Propofol has previously demonstrated anti-emetic properties; 
often being used in total intravenous anesthesia in patients with known PONV. 
This pilot study investigated if the administration of a sub-hypnotic dose of 
propofol, as an anti-emetic during emergence period of anesthesia, affects PONV rates 
during the immediate post-operative period.  A randomized, blinded, controlled 
comparison group study was conducted to investigate the use of propofol as an 
antiemetic.  A group of 10 (N=10) ASA I or II patients, aged 18-65, undergoing 
laparoscopic, gynecologic surgery were examined using a verbal analog scale.  These 
patients were randomly assigned to a control group which received ZofranTM only, or a 
treatment group which received ZofranTM and propofol. 
iii 
 
A paired samples t-test failed to reveal a statistically reliable difference between 
the mean of the CX (M = 0, s = 0) and TX (M = 2.00, s = 4.472) group created during 
this pilot study, t(8) = 1.000, p = .0.174, α = .05.  A chi-square test was performed and no 
relationship was found between the CX and TX groups in relation to vomiting, X2 (1, N 
= 10) = 1.111, p =0.146.  Thus, the pilot study determined there was no statistical 
significance of preventing PONV with sub-hypnotic doses of propofol.
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CHAPTER I 
INTRODUCTION 
Background 
 Postoperative nausea and vomiting was first identified in surgical patients in 1914 
and remains a major complication of anesthesia (Butterworth, Mackey, & Wasnick, 2013; 
Forren, 2014).  It is predicted that PONV affects 20-30% of all surgical patients 
(Butterworth et al., 2014).  Risk factors often related with PONV are female gender, 
laparoscopy, general anesthesia, opioids, volatile agents, and post-operative pain 
(Butterworth et al., 2013).  However, all of these risk factors are frequently encountered 
in the clinical setting (Butterworth et al., 2013).  As research has evolved, a commonly-
used anesthetic, propofol, has been identified to have antiemetic properties when used as 
an induction agent or supplemental intravenous anesthetic (Forren, 2014). 
Clinical Question 
 In adult female patients undergoing laparoscopic gynecologic surgeries, how does 
the administration of a sub-hypnotic dose of propofol, as an anti-emetic at extubation, 
affect PONV rates during the immediate post-operative period?  This research question 
entails many variables that were examined individually in regards to the treatment of 
PONV in the selected surgical population.  
Problem Statement 
 The experience of PONV can decrease satisfaction scores of the patient and can 
also account for a loss of revenue (Prevention of PONV, 2013; Thompson, 1999). The 
incidence of PONV can cause a financial loss of approximately $415 per patient, related 
to increased personnel time, supplies, and drugs (Prevention of PONV, 2013; Thompson, 
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1999).  Many other complications can develop as a result of PONV such as: increased 
anxiety, decrease in oxygen saturation level, hypovolemia, electrolyte imbalances, 
incisional pain, increased risk of incisional dehiscence, increased intracranial pressure, 
risk of aspiration, and many other complications (DeLeskey, 2009; Forren, 2014; 
Prevention of PONV, 2013; Thompson, 1999).   
These complications are not only harmful to the patient, but can increase post-
operative recovery time. The incidence of PONV can also cause increased patient 
utilization of the post-anesthesia recovery unit (PACU) (DeLeskey, 2009; Prevention of 
PONV, 2013; Thompson, 1999).  An increase in PACU time can cause a delay in the 
operating room schedule due to the limited availability of recovery room beds 
(Thompson, 1999).  During development of the solution to the identified clinical problem 
of PONV, these variables were accounted for in the proposed plan to increase curiosity of 
the sponsoring organization. 
Purpose of Project 
 While recognized as a common complication of anesthesia for many decades, 
PONV remains a notable clinical problem of anesthesia practice (DeLeskey, 2009; 
Hambridge, 2012; Thompson, 1999).  Among patients that have multiple risk factors, or 
are considered high-risk patients, PONV incidence can be as high as 70% (Deleskey, 
2009; Hambridge, 2012).  Laparoscopic procedures increase the frequency of PONV due 
to insufflation of the abdomen and bowel manipulation (Butterworth et al., 2013; Joshi & 
Cunnignham, 2013; Pawar, Sarkar, & Dewoolkar, 2009).  Thus, laparoscopic surgical 
patients were identified as a high-risk patient population for PONV, and the 
3 
 
 
 
recommendation is to implement a multimodal antiemetic approach in this population 
(Joshi & Cunnignham, 2013).  
The goal of this project was to use of sub-hypnotic doses of propofol to decrease 
PONV rates in the immediate post-operative period in females undergoing laparoscopic, 
gynecologic surgery.  By decreasing the rates of PONV, potential complications can be 
avoided, and patient satisfaction will increase.  The goal was an improvement in patient 
outcomes following laparoscopic, gynecologic surgery through the implementation of the 
selected intervention,  
Needs Assessment 
 PONV is a common complication of anesthesia, with an incidence of 20-30% and 
requires prevention and treatment measures by the anesthesia provider (Butterworth, 
Mackey, & Wasnick, 2013; Forren, 2014).  By decreasing the rate of PONV, patient 
satisfaction will increase, patient outcomes will improve, facility costs will decrease, and 
the surgical center can have higher productivity.  In implementing a clinical protocol to 
decrease PONV by administering sub-hypnotic doses of propofol in addition to ZofranTM, 
the purpose was to determine if this intervention improved patient outcomes by 
decreasing the rate of PONV in the immediate post-operative period.  While the 
decreased rates of PONV will be the main goal in this project, financial consideration 
was also examined to determine if there was a cost savings or higher expense with the 
intervention. 
Effectively preventing and treating PONV not only increases patient safety and 
satisfaction, but also increases the efficiency and productivity of the operating room (OR) 
and PACU (Fombeur et al., 2002; Thompson, 1999).  Increasing proficiency and 
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productivity were a strength of the intervention, which helped to encourage buy-in by the 
clinical facility.  The incidence of PONV cannot only decrease satisfaction scores of the 
patient affecting their view of the quality of care they received, but can also account for a 
loss of revenue (Thompson, 1999).   
Therefore, by using propofol as an antiemetic, increased patient satisfaction and 
decreased healthcare costs could theoretically improve due to decreasing incidence of 
PONV.  However, achieving the appropriate balance between the dosage of the sub-
hypnotic doses of propofol and the effectiveness of PONV prevention is necessary for 
cost-effective care.  The weakness of the intervention implementation was a perceived 
increased cost of care associated with the use of propofol as an antiemetic. 
An opportunity for this study was the desire by the ambulatory surgery center 
(ASC) or hospital to improve patient outcomes and decrease discharge time.  This desire 
allowed the study to try to achieve these goals by decreasing PONV rates and recovery 
times in the PACU.  A threat, however, was the approval process and cooperation of the 
center’s staff in the implementation of the clinical project.  Without the support and 
participation of the clinical staff, the study would not have been complete.  
In developing the research question, adult female patients undergoing 
laparoscopic gynecologic procedures were identified as the target population.  Female 
patients undergoing gynecologic laparoscopic surgery are at an increased risk of PONV 
due to: female gender, laparoscopic surgery, intra-abdominal surgery and post-operative 
pain; which are all considered risk factors for PONV (Butterworth et al., 2013; Joshi & 
Cunningnham, 2013).  The additive result of each risk factor for PONV in this population 
places them at an even higher risk for PONV, which means they have a 70% possibility 
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of developing the complication (Deleskey, 2009).  In has been reported that gynecologic 
surgeries carry the highest risk for PONV with an incidence of 60-83% in this patient 
population (Ramanathan, Augustus, Thiruvengadam, Sundaram, & Deepalakshmi, 2003).  
Further, the majority of gynecologic surgeries are now being performed on an outpatient 
basis.  Outpatient surgery requires the provider to prevent effectively or quickly provide 
treatment for PONV for rapid discharge from the surgery center (Ramanathan et al., 
2003). 
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CHAPTER II 
REVIEW OF RELATED LITERATURE 
 Since being first identified in scholarly publication in 1914, postoperative nausea 
and vomiting (PONV) is still one of the most frequent complication of anesthesia 
(Butterworth et al., 2013).  PONV is estimated to affect 20-30% of all surgical patients 
(Butterworth et al., 2013).  PONV is a complication of anesthesia that is not only 
undesirable, but also delays recovery in the post anesthesia care unit (PACU) (Borgeat, 
Wilder-Smith, Saiah, & Rifat, 1992; Gan et al., 1996; Lambert, Wakim, & Lambert, 
2009; Thompson, 1999).  The complication of PONV also decreases patient comfort, 
delays discharge home, and can result in more serious complications such as aspiration 
pneumonia or surgical wound dehiscence (Borgeat, Wilder-Smith, Saiah, & Rifat, 1992; 
Gan et al., 1996; Lambert, Wakim, & Lambert, 2009; Thompson, 1999).  Even as 
anesthesia techniques and equipment have improved drastically from the period of ether 
anesthesia, PONV still occurs with high frequency (Gan et al., 1996; Lambert et al., 
2009).  PONV is estimated to have an incidence of 25-30% for all surgeries, with up to 
70% in high-risk patients such as women undergoing gynecological surgery (Butterworth 
et al., 2013; Kovac, 2000; Kovac, 2006; Lambert et al., 2009; Thompson, 1999).   
PONV Mechanism 
 PONV is a common occurrence in anesthesia, partly due to the narcotic agents 
that are used during the procedures for pain control (Lambert et al., 2009).  While PONV 
is often multifactorial in development, it is often caused by the stimulation of the 
chemoreceptor trigger zone (CRTZ) which lies in the fourth ventricle of the brain 
(Lambert et al., 2009; Norred, 2003; Thompson, 1999).  Nausea initiates in the CRTZ 
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due to its locations in the area postrema below the fourth ventricle and the solitary tract 
nucleaus (Sharkey & Wallace, 2011; Watcha & White, 1992).  The highly vascularized 
CRTZ area has no blood-brain barrier; allowing reaction to substances in the blood and 
cerebral spinal fluid (CSF) (Pellegrini, Deloge, Bennett, & Kelly, 2009; Sharkey & 
Wallace, 2011; Thompson, 1999; Watcha & White, 1992).  The CTRZ has receptor sites 
for dopamine, opioids, serotonin, and enkephalins (Kovac, 2000; Norred, 2003; Sharkey 
& Wallace, 2011, Watcha & White, 1992).  Additionaly, histaminic and muscarinic 
cholinergic receptors that can be stimulated by substances in the blood, and CSF are 
located in the CTRZ (Kovac, 2000; Norred, 2003; Sharkey & Wallace, 2011, Watcha & 
White, 1992). 
 The stimulation of the receptors in the CRTZ often are initiated by periphery 
components such as the oropharynx, gastrointestinal tract, peritoneum, and genitalia 
(Thompson, 1999).  However, central stimulation of the vestibular apparatus, cerebral 
cortex, or labyrinthine can also stimulate nausea and vomiting (Thompson, 1999).  
Nausea is excitation of the CTRZ and vomiting center, which can occur by: “irritative 
impulses coming from the gastrointestinal tract, impulses that originate in the lower brain 
associated with motion sickness or impulses from the cerebral cortex to initiate vomiting” 
(Hall & Guyton, 2011, p. 804).  The CTRZ communicates central cerebral stimuli to the 
vomiting center (VC) (Kovac, 2000).  The VC receives inputs from “multiple afferent 
sensory pathways including cranial nerve (CN) X the vagus nerve, CN VIII the vestibular 
nerve, the limbic system and the CRTZ” (Thompson, 1999, p. 1131).  Since the CTRZ is 
the area that comprises of the receptors that cause PONV, this area was the focus of this 
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study.  Nausea is considered a protective reflex and is subjective to the patient; nausea 
can be experienced alone or in conjunction with vomiting or retching (Kovac, 2000).   
 Vomiting or retching can sometimes follow nausea stimulus.  Vomiting, or 
emesis, is a method in which the upper gastrointestinal tract expels its contents (Hall & 
Guyton, 2011; Kovac, 2000; Watcha & White, 1992).  This often occurs when the upper 
digestive tract is over distended, irritated, or hyperactive (Hall & Guyton, 2011; Kovac, 
2000; Watcha & White, 1992).  Vomiting is a complex process in which the body can 
stop the digestion and further ingestion of gastric contents by expelling them via the 
oropharynx (Kovac, 2009; Sharkey & Wallace, 2011).  Vomiting has three phases: the 
pre-ejection, ejection, and post-ejection phases (Sharkey & Wallace, 2011; Watcha & 
White, 1992).   
 The pre-ejection phase is when antiperistalsis begins, which is movement up the 
digestive tract (Hall & Guyton, 2011; Watcha & White, 1992).  Antiperistalis is 
accompanied by salivation, swallowing, pallor, and tachycardia (Hall & Guyton, 2011; 
Watcha & White, 1992).  This phase is then followed by the ejection phase, which 
consists of retching and vomiting (Watcha & White, 1992).  Retching is a contraction of 
the abdominal and intercostal muscles, along with the rhythmic action of the respiratory 
muscles against a closed glottis (Sharkey & Wallace, 2011; Watcha & White, 1992).  
During this phase the hiatal portion of the diaphragm stays contracted, which increases 
intra-abdominal pressure (Watcha & White, 1992).  Ejection of gastric contents occurs 
when the glottis opens, the esophageal sphincter relaxes, and the rectus abdominis and 
external oblique muscles contract (Hall & Guyton, 2011; Sharkey & Wallace, 2011; 
Watcha & White, 1992). 
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 The ejection phase is followed by physiologic responses to return the body back 
to a calm phase; this can be absent of or accompanied by nausea (Watcha & White, 
1992).  The complex process of vomiting requires the coordination of several muscles 
and processes (Watcha & White, 1992).  In the post-operative patient, the metabolic 
expenditure and possible side effects of vomiting place the patient at higher risk for 
complications.  Thus, the high-risk patient must be identified prior to surgery to prevent 
PONV complications during the recovery phase. 
PONV Risk Factors 
 To effectively prevent PONV, high-risk patients must be identified 
preoperatively.  Patients can be at high risk for PONV based on underlying physical 
disease, the surgical procedure, the duration of anesthesia, or the type of anesthetic 
administered (Gupta, Wakhloo, Lahori, Mahajjan, & Gupta, 2007; Kovac, 2000; Sinclair, 
Chung, & Mezie, 1999; Watcha & White, 1992; Wender, 2009).  Risk assessment tools 
are available in identification of patients at high-risk for PONV such as the one 
developed by Apfel et al. (1998).  By using these scoring systems, objective data can be 
collected to identify potential high-risk patients, which allows for adequate preventative 
treatment (Hambridge, 2012). 
Obesity 
 Obesity is considered an increased risk of PONV due to the accumulation of 
anesthetic gases in the adipose tissue; this accumulation can delay emergence from 
anesthesia and the return of protective airway reflexes (Hambridge, 2012; Thompson, 
1999; Watcha & White, 1992).  Due to the obesity epidemic, this can present a problem 
in preventing PONV.  Obese patients can also have larger residual gastric volumes that 
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place them at a higher risk for PONV (Thompson, 1999; Watcha & White, 1992).  Also, 
obese individuals can present with airway difficulties, which can increase the risk of 
gastric inflation resulting in higher incidence of PONV (Watcha & White, 1992). 
Age 
 PONV tends to have higher incidences in younger children than that of adults 
(Gan et al., 2006; Watcha & White, 1992).  However, this is contradicted by Thompson 
(1999), who reported that children were less likely to experience PONV than that of their 
adult counterparts.  Thompson (1999) also states that elderly adults, greater than 55 years 
old, were less likely to experience PONV for the same operation in a younger individual 
having the operation.  However, the majority of the evidence supports that younger 
children have a higher incidence of PONV when compared to adults (Gan et al., 2006; 
Watcha & White, 1992). 
Gender 
 There is a consensus that women have a higher incidence of PONV over that of 
men (Gan et al., 2006; Hambridge, 2012; Thomspon 1999; Watcha & White, 1992).  
Females are two to three times more likely to experience PONV after puberty, with more 
severe vomiting (Thompson, 1999).  The incidence of PONV increases due to hormonal 
changes when procedures occur during the menstrual cycle (Watcha & White, 1992). 
Surgical Procedure and Duration 
 Certain surgical procedures also carry higher risk of PONV such as: 
gynecological, middle ear, laparoscopic surgeries, reproductive, gallbladder, head, neck, 
and strabismus surgery (Gan et al., 2006, Hambridge, 2012, Thompson, 1999; Watcha & 
White, 1992).  The majority of PONV documented occurred during ovum retrieval 
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procedures (Watcha & White, 1992).  In addition to the type of procedure, the duration of 
anesthesia also has significant effects on PONV rates (Gan et al., 2006, Hambridge, 2012, 
Thompson, 1999; Watcha & White, 1992).  The patient has increased exposure to emetic 
agents such as opioids and volatile agent with a longer duration of anesthesia (Gan et al., 
2006, Hambridge, 2012, Thompson, 1999; Watcha & White, 1992). 
Smoking 
 Non-smokers are described as having a higher risk of PONV than that of smokers 
(Gan et al., 2006, Hambridge, 2012, Thompson, 1999; Watcha & White, 1992).  In a 
study conducted by Chimbira & Sweeney (2000), enzyme induction caused by smoking 
is believed to be the reason that smokers have a lower incidence of PONV.  Chimbira & 
Sweeny (2000) reported that “only 6% of smokers developed PONV compared to 15% of 
nonsmokers” (p. 540). 
Additional Factors 
 While the above mentioned are the main factors for PONV, there are additional 
factors that can place a patient at high risk.  Some of the additional factors include pain, 
delay gastric emptying, hypotension, hypovolemia, migraines, and early ambulation after 
surgery (Gan et al., 2006, Hambridge, 2012, Thompson, 1999; Whatcha & White, 1992).  
All of the factors are additive in determining a patient's risk for PONV. 
Propofol 
 Propofol has been noted to decrease PONV among patients who receive it; 
however, in the first study to examine the direct antiemetic properties of propofol, 
Borgeat et al. (1992), demonstrated that in a randomized, double-blind, placebo-
controlled study that propofol had significant direct antiemetic properties.  In this study, 
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the placebo that was used was an intra-lipid to help demonstrate and set apart the 
propofol and its antiemetic properties (Bargeat et al., 1992).  This finding was also 
supported by a double-blinded, randomized comparison of ondansetron and 
intraoperative propofol to prevent PONV conducted by Gan et al. (1996), which showed 
that the maintenance of anesthesia with propofol is more efficient in preventing PONV 
than ondansetron.  The studies conducted by Borgeat et al. (1992) and Gan et al. (1996), 
both support the antiemetic properties of propofol and its use in anesthesia management. 
 While propofol is known to have antiemetic properties, the site of action is still 
unknown (Borgeat et al., 1992; Gan et al., 1996; Gan et al., 1997).  In a study conducted 
by Gan et al. (1996) and Gan et al. (1997), it was postulated that the mechanism of action 
is that of an anti-dopaminergic.  Despite the unknown mechanism of action, propofol has 
been demonstrated to have antiemetic properties (Borgeat et al., 1992; Gan et al., 1996; 
Gan et al., 1997).  There is a significantly decreased incidence of PONV when infused as 
part of the anesthetic regimen (Borgeat et al., 1992; Gan et al., 1996; Gan et al., 1997). 
 Once propofol was proven to have antiemetic properties, the next question that 
developed was how can it be used solely as an antiemetic?  Sub-hypnotic doses of 
propofol were used by Gan et al. (1997) to determine the plasma concentration that was 
needed to manage efficiently and prevent PONV.  Gan et al. (1997) determined that a 
plasma concentration of 343 ng/ml of propofol was necessary to achieve the antiemetic 
effects of propofol effectively.  This plasma level causes no increase in sedation and can 
be accomplished by a 10 mg bolus followed by an infusion of 10 ug/kg/min (Gan et al., 
1997).  This propofol sub-hypnotic dose is supported the previous evidence by Borgeat et 
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al. (1992), which demonstrated that 10 mg sub-hypnotic doses of propofol, for patients 
weighing 50-80 kg, demonstrated direct antiemetic effects against PONV. 
Propofol Side Effects 
 The use of sub-hypnotic doses of propofol is not associated with any increased 
sedation, cardiovascular changes, respiratory depression, or pruritus (Borgeat et al., 1992; 
Gan et al., 1997).  There is some pain on injection associated with the use of propofol; 
however, this pain was only slight (Borgeat et al., 1992).  Since the administration of the 
sub-hypnotic dose given to prevent PONV occurs under anesthesia, no pain is 
experienced by the patient.  If the patient is awake when receiving the propofol dose, a 
study conducted by Picard and Tramer (2000) demonstrated that lidocaine (0.5mg/kg IV) 
with a rubber tourniquet on the arm 30-120 seconds before the propofol injection can 
decrease pain of administration.  In 60% of the patients, this technique with lidocaine 
prevented pain with the injection of propofol (Picard & Tramer, 2000). Alternatively, in a 
study conducted by Scott, Saunders, and Norman (1988), it was found that the most 
effective technique to prevent pain upon injection was by injecting into a large vein in the 
antecubital fossa.  There was also an acknowledgment that the use of lidocaine also 
decreased pain upon injection (Scott et al., 1988). 
   While this small amount of pain upon injection was noted, no other 
complications were noted with the use of propofol, which places it above other antiemetic 
medications (Borgeat et al., 1992).  Alternative antiemetic medications can cause 
prolongation of the Q-T interval and cause headaches (Borgeat et al., 1992).  
Ondansetron or ZofranTM, is a 5-hhydroxtryptamine (5-HT) antagonist that is similar to 
serotonin (Bodner & White, 1991; Fowler & Spiess, 2013; Nicholau, 2011; Odom-
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Forren, 2014; Sharkey & Wallace, 2011).  Ondansetron is a very efficient agent in 
treating mild to moderate PONV, but does have some Q-T prolongation (Bodner & 
White, 1991; Fowler & Spiess, 2013; Nicholau, 2011; Odom-Forren, 2014; Sharkey & 
Wallace, 2011).  In a study conducted by Bodner & White (1991), a group of patients that 
received ondansetron had a 41% lower incidence of PONV than the patient who did not.  
However, the ondansetron group still had a considerably high number, 43%, of all 
patients who needed a rescue antiemetic in the recovery room (Bodner & White, 1991). 
 Ondansetron had been shown to be more efficient when administered with 
another antiemetic medication, such as dexamethasone (Shora, Gurcoo, Farooqi, Qazi, & 
Mehrah-ud-Din, (2008).  Droperidol, a dopamine antagonist, previously was the choice 
for antiemetic treatment (Odom-Forren, 2014).  However, droperidol has since had a 
black box placed on it by the Food and Drug Administration (FDA) due to QT 
prolongation (Odom-Forren, 2014).  While the association of Q-T prolongation is with 
higher dosing regimens, which are much greater than the dose required to prevent PONV; 
it is still considered more dangerous than ondansetron that can have the same effect on Q-
T prolongation (Odom-Forren, 2014).  Propofol is a safe alternative or adjunct to prevent 
these complications. 
 Since antiemetic drugs have different sites of action, multi-modal treatment can 
be beneficial to prevent PONV in high-risk patients (Norred, 2003; Watcha & White, 
1992).  By implementing a multi-modal therapy regimen, lower doses of antiemetic 
agents can be used due to the additive effects of the different drugs to prevent side effects 
(Norred, 2003; Watcha & White, 1992).  However, care must be taken to avoid the use of 
multiple drugs with the same site of action to prevent and increased incidence of side 
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effects (Watcha & White, 1992). Thus, the addition of propofol as an antiemetic could 
prove very useful in multi-modal treatment for PONV. 
 One potential complication is a possible reaction with the administration of 
propofol to a patient with an egg or soy allergy (Murphy, Campbell, & Baines, 2011; 
Nagelhout, 2014).  Propofol contains egg lecithin/phosphatide and soy oil in its lipid 
suspension (Murphy et al., 2011; Nagelhout, 2014).  However, the egg 
lecithin/phosphatide and soy oil is considered unlikely to cause an allergic reaction 
(Murphy et al., 2011; Nagelhout, 2014).  Besides the proteins from the egg whites that 
could cause an allergic reaction, the propofol formulation contains heated egg yolk 
(Murphy et al., 2011; Nagelhout, 2014).  While there is no data that supports the 
avoidance of propofol in egg or soy allergic patients, the consensus differs between 
countries on whether or not propofol should be administered to these individuals 
(Murphy et al., 2011; Nagelhout, 2014).  Clinicians tend to err on the side of caution and 
avoid its use in such individuals. 
 Since propofol is known to have antiemetic properties, many would ask why not 
use it for all surgical cases?  Fombeur et al. (2002) examined the cost comparison and 
effectiveness of propofol anesthesia versus that of desflurane.  While desflurane was 
cheaper than propofol in providing anesthesia, $28 versus $45 respectively, patients in 
the desflurane group was over five times more likely to experience PONV (Fombeur et 
al., 2002).  Thus, the volatile agent patients would require more nursing time, additional 
medications, longer PACU times, and have lower patients satisfaction scores (Fombeur, 
et al., 2002).  As healthcare providers, we must carefully examine the risk factors to 
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ensure that proper use of propofol is used to help improve patient outcomes while also 
minimizing healthcare costs. 
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CHAPTER III 
METHODOLOGY 
Theoretical and Conceptual Framework 
 Neuman’s system model was the conceptual model for this study.  Neuman’s 
system model has two main factors: stress and the systematic feedback loops (Whetsell, 
Gonzalez, & Moreno-Fergusson, 2011).  In Neuman’s model, the individual is examined 
as a holistic being interacting with its environment; however, it is the stress that the 
individual encounters in its environment can disrupt a person's homeostasis (Martin, 
2006).  Neuman believed that if the individuals needs were obtained, that the individual 
would have wellness (Martin, 2006; Whetsell et al., 2011).  However, Neuman defined 
the nurse’s role as to assess, manage, and provide interventions at any time that a stressor 
was identified or perceived (Martin, 2006). 
 Neuman’s conceptual model is very applicable to the anesthesia specialty because 
of the impact that environmental factors have on patients under anesthesia.  As anesthesia 
providers, an appropriate pre-operative assessment must be completed to develop an 
appropriate anesthesia plan to transition the patient throughout the perioperative period 
with as little disturbance by stress as possible.  For PONV, by adequately identifying 
high-risk individuals and implementing a preventative treatment modality, such as sub-
hypnotic doses of propofol at extubation, the goal is that the occurrence of PONV will 
decrease.  Based on Neuman’s model, the stressor of PONV is the surgery or anesthesia 
provided along with any factors that would place the patient at high risk for PONV.  
Advanced practice nurses must have minimal stress for the benefit and wellness of the 
patients. 
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 The guiding model used for this project was the logic model (Appendix C).  The 
logic model “is a systematic and visual way to present and share your understanding of 
relationships among the resources you have” (W.K. Kellogg, 1998, p.1).  The logic 
model serves as a conceptual map that guides program development by identifying and 
utilizing interpersonal and institutional investments (W.K. Kellogg, 1998). 
 The logic model maps how a program or project should work (W.K. Kellogg, 
1998).  The logic model can be used to plan effectively, develop, implement, and 
disseminate results of a project by creating a systematic and logical pattern to follow 
(W.K. Kellogg, 2014).  The logic model visually demonstrates and helps to organize 
needed activities and the order of events (W.K. Kellogg, 1998).  The logic model was 
used to guide the development and implementation of this project in the clinical setting. 
Setting 
 The clinical setting for the implementation of this intervention was an 
obstetrics/gynecologic (ob/gyn) surgical department located in a Level 2 trauma center in 
Hattiesburg, Mississippi.  This specialized surgical department setting provided the ideal 
environment since the majority of laparoscopic gynecologic surgeries are now being 
performed in specialty departments that are capable of inpatient and outpatient 
procedures (Buchh et al., 2009).  The ob/gyn surgical department normally provides care 
for patients that are class I and class II as set forth by the American Society of 
Anesthesiologists (ASA) (Buchh et al., 2009).  This classification of patient status means 
there are no other diseases present, or the patient has only mild systemic disease, 
respectively (Sweitzer, 2011).  This environment provided an ideal population to 
implement the proposed evidenced based practice (EBP) intervention.  By using propofol 
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as an antiemetic in sub-hypnotic doses, there was a possibility of PONV prevention with 
a routinely used drug in anesthesia.  Propofol is an excellent choice for gynecologic 
anesthesia due to a quick recovery of sedation effects with continuance of antiemetic 
properties for a better outcome, increased patient satisfaction, and faster discharge 
(Buchh et al., 2009; Ramanathan et al., 2003). 
Target Outcome 
 The desired outcome for this identified population was to decrease the incidence 
of PONV in the immediate post-operative period with minimal side effects.  The goal 
was that PONV rates would decrease due to administering propofol at extubation.  This 
result was measured by evaluating for the incidence of PONV in the propofol 
intervention group based a verbal analog scale for nausea and physical assessment for 
vomiting, versus that of the ondansetron only group.  Propofol is known to be an agonist 
for the y-aminobutyric acid (GABA) receptor, which exerts as an inhibitory 
neurotransmitter (Nagelhout, 2014; Patel, Patel, & Roth, 2011).  While the mechanism of 
the antiemetic effect is uncertain, propofol is known to have some antiemetic effects 
(Nagelhout, 2014; Patel, Patel, & Roth, 2011, Ramanatham et al., 2003; White & Eng, 
2013).  However, in a limited study conducted by Ramanathan et al. (2003), propofol in 
sub-hypnotic doses grossly reduced the incidence of PONV in a treatment group of 20 
women undergoing gynecologic surgery versus that of the control group.  This study 
provided a fundamental basis on for generation of further EBP research. 
 By using propofol as an antiemetic, there is a possibility to avoid some 
complications that are associated with other commonly used drugs.  One of the best drugs 
for PONV treatment, droperidol, was labeled with a black box warning by the Food and 
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Drug Administration (FDA) due to possible fatal QT prolongation which can lead to 
torsades de pointes arrhythmias (Norred, 2002; Prevention of PONV, 2013).  This black 
box warning by the FDA stopped the routine use of droperidol as an antiemetic due to the 
risk of possible litigation due to complications (Norred, 2002).  However, the 
medications that replaced droperidol in routine practice, ondansetron and granisetron, 
also have the adverse side effects of prolongation of the QT interval that is dose 
dependent (Prevention of PONV, 2013).  Another problem with the 5-HT3 antagonist, 
ondansetron and granisetron, is that they are best used in practice as a possible prevention 
of PONV due to the possibility of delay in onset (Prevention of PONV, 2013).  
Preventative treatment of PONV in all patients is controversial due to the costs that are 
associated (Prevention of PONV, 2013).  These adverse effects are not an issue with 
propofol, which makes it an ideal antiemetic drug. 
Barriers 
 There are many obstacles to effective communication and collaboration in the 
clinical environment that affect the improvement of patient outcomes.  One major 
potential barrier to the collaboration for this clinical project was the regulatory 
disagreement between the anesthesiologists and nurse anesthetists.  While the two 
professions should be able to collaborate to improve patient outcomes, often physicians 
want to protect their field and will not support the endeavors of the advanced nursing 
provider (Chism, 2013).  However, the buy-in of the physician in the anesthesia group 
was a crucial step because often times physicians are associated with the financial 
accomplishment of the hospital; thus, they are normally a majority of the leadership team 
and board of directors (Chism, 2013).  Hence, without the support of the physicians, there 
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was little hope of receiving interest from the hospital or gaining approval for 
implementation.  This potential barrier was not an issue for the implementation of this 
clinical project.  There was full support by the physician staff not only of the department 
of anesthesia, but also of surgery.   
 The objective was to obtain interest at a hospital to perform the proposed EBP 
intervention to assess if better outcomes are achieved by decreasing the incidence of 
PONV in the immediate post-operative period with the use of propofol.  The goal was to 
decrease PONV in the immediate post-operative period that had the possibility of 
decreasing healthcare costs.  By demonstrating a possible improvement in patient 
outcomes and a reduction in costs; the institution was very amicable in allowing the 
implementation of the clinical project and possibly support the change of clinical practice 
if the results supported the intervention. 
Population 
 Recruitment of females between the ages of 18-65, undergoing gynecologic, 
laparoscopic surgery supplied the subjects for this study.  A total of 40-50 subjects were 
the goal, with 20-25 subjects in each group.  However, due to limitations and delays of 
obtaining university research approval, ten subjects (N=10) were recruited with five 
subjects in each group.  Inclusion criteria included: female, gynecologic surgery, 
laparoscopic surgery, American Society of Anesthesiologist (ASA) physical status (PS) 1 
or 2, and no history of PONV.  Exclusion criteria included: diabetes, ASA 3 or 4, history 
of PONV, systolic blood pressure less than 90 mmHg, a known allergy to eggs, sulfites, 
or soybeans, non-English speaking individuals, hiatal hernia, diagnosed with 
gastroparesis, pregnant, currently incarcerated, and patients who refuse to sign informed 
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consent.  A convenience sample was obtained at the surgical department.  There was a 
random assignment of patients to one of two groups, which were blinded to the PACU 
nurses after gaining consent. 
 In developing the research question, adult female patients undergoing 
laparoscopic gynecologic procedures were identified as the target population.  It has been 
identified that the female population undergoing gynecologic laparoscopic surgery are at 
higher PONV risk due to: female gender, laparoscopic surgery, intra-abdominal surgery 
and post-operative pain (Butterworth et al., 2013; Joshi & Cunningnham, 2013).  The 
additive result of each risk factor for PONV in this population places them at an even 
higher risk for PONV, which means they have a 70% possibility of developing the 
complication (Deleskey, 2009).  It has been reported that gynecologic surgeries carry the 
highest risk for PONV, with an incidence of 60-83% in this patient population 
(Ramanathan, Augustus, Thiruvengadam, Sundaram, & Deepalakshmi, 2003).   
 The ASA PS classification system, developed in 1941, has become a standard in 
the field of anesthesia.  The intent of this classification system is to assess the general 
physical status of the patient during the preoperative evaluation (Aronson, McAuliffe, & 
Miller, 2003; Owens, Felts, & Spitznagel, 1978).  The design of the system was to 
standardize patient classification for statistical methods and consistency in hospital 
records (Owens et al., 1978).  This system does not identify surgical or anesthetic risk for 
the proposed procedure as it is often misused by anesthesia personnel (Aronson et al., 
2003).  While the system does have some bias and interrater reliability issues, it is still 
considered the standard classification system in anesthesia (Aronson et al., 2003).   
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 The ASA PS system was used to classify patient status in the preoperative holding 
area (Table 1).  The ASA PS 1 patient is one that is a normal healthy patient, while the 
PS 2 patient has mild systemic disease that is well controlled and creates no functional 
deficits (American Society of Anesthesiologist, 2014; Aronson et al., 2003).  Since this 
study will exclude patients with ASA PS 3, 4, and 5, patients who have diseases that 
result in functional deficits, a constant threat to life, and not expected to live without the 
procedure will not be included in the study (Owens et al., 1978).  This inclusion criterion 
will limit to the population to healthy subjects with controlled systemic diseases, thus 
preventing the inclusion of patients with diseases of a significant nature. 
Table 1 
American Society of Anesthesiologist Classification System 
Physical Status Description 
ASA PS 1 A normal healthy patient. 
ASA PS 2 A patient with a mild systemic disease. 
ASA PS 3 A patient with a severe systemic disease. 
ASA PS 4 A patient with a severe systemic disease that is a constant threat to 
life. 
ASA PS 5 A morbid patient who is not expected to live without operation. 
ASA PS 6 A patient declared brain dead whom organs are being harvested. 
E Emergent 
 
Note. ASA= American Society of Anesthesiologist. PS= Physical Status 
 The study included patients who had a negative history for PONV.  Excluded 
were patients who had a previous history of PONV as this was an increased risk factor for 
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subsequent PONV; this high-risk patient category require the use of a multimodal 
approach to the prevention of PONV (Gan et al., 2006; Hambridge, 2013).  By excluding 
high-risk PONV patients, appropriate care can be given to them while the accuracy of the 
study could be maintained. 
 Excluded were patients who had documented allergies to soybeans and eggs, due 
to the lecithin content of propofol (Murphy, Campbell, Baines, & Mehr, 2011).  Lecithin 
is contained eggs, soybeans, or other vegetables, which are used in propofol as an 
emulsifying agent (Murphy et al., 2011).  While there is no consensus on whether 
patients allergic to eggs or soybeans are at increased risk with propofol use, and the 
product label reads differently between countries, practitioners practice •cautiously and 
avoid the agent in this population (Nagelhout, 2013).  Patients also allergic to sulfites 
could have allergic reactions to generic variations of propofol, thus also requiring 
exclusion from the study (Nagelhout, 2013).  While trade name propofol does not contain 
sulfites, to ensure, the patient received this formulation of propofol would have 
complicated logistics.  By eliminating this population, there would be a limited number 
of excluded individuals, if any, due to the low incidence of this allergy (Nagelhout, 
2013).    
 Patients who were hypotensive, as defined by a systolic blood pressure less than 
90 mmHg, were excluded from this study.  There is a dose-dependent hypotensive effect 
with the use of propofol (Patel, Patel, & Roth, 2011).  Propofol could alter the 
baroreceptor reflex, cause vasodilation, and depress myocardial contraction, which results 
in hypotension (Patel et al., 2011).  Thus, it is advised that propofol be used with extreme 
caution in patients who are experiencing hypotension (Patel et al., 2011). 
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 Other individuals excluded from the study were those with gastroparesis, diabetes, 
and hiatal hernia; non-English speaking and those who refuse to sign the consent form.  
Patients with diabetes could have autonomic neuropathy that can decrease gastric motility 
and can lead to gastroparesis (Inzucchi & Sherwin, 2012; Watcha & White, 1992). 
Gastroparesis, autonomic neuropathy with diabetes, and hiatal hernia are at an increased 
risk of gastric fluid aspiration (Marley, Calabrase, & Thompson, 2013; Watcha & White, 
1992).  These patient populations were avoided based upon an increased risk of aspiration 
and vomiting post-operatively due to gastric residual volumes (Marley, Calabrase, & 
Thompson, 2013).  The exclusion of Non-English speaking individuals was due to 
language barriers and the lack of certainty of complete understanding of the information 
provided to them.   
 Finally, anybody who refused to sign a consent form, was pregnant, or currently 
incarcerated was excluded based on research protocols as set forth by The University of 
Southern Mississippi and the institutional review board (IRB).  Pregnancy and 
incarcerated individuals are considered highly vulnerable; thus, they were not included in 
this study.  This exclusion ensured that potentially vulnerable individuals remained 
protected. 
Sampling 
 A convenience sampling method was employed, at an ob/gyn surgical department 
in Hattiesburg, Mississippi, to enroll subjects into the pilot study.  Convenience sampling 
can introduce bias into the sample, but is often used in a pilot study to help develop more 
in-depth protocols for larger studies (Houser, 2008; Grove et al., 2013).  Participants 
were randomly assigned a group after they have enroll in the study, to help control bias in 
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the sample (Houser, 2008).  Data was collected to allow for an adequate description of 
the sample to identify any possible prejudice (Grove et al., 2013). 
 Recruitment of the subjects occurred at the surgical center through personal 
communication.  The initial communication is the most important in this type of 
recruitment; thus, it should be pleasant, culturally sensitive, informative, and 
nonaggressive (Grove et al., 2013).  The communication should regard the subject as a 
valuable resource for the researcher (Grove et al., 2013).  The patient was ensured that if 
he/she refuses to complete the study, the surgical center staff would still provide high-
quality care without the effect of their decision.  Should a participant decline to consent 
to be in the study, its acceptance was elegant, and care was provided unaffected (Grove et 
al., 2013). 
 A total of 10 subjects comprised the sample used for this pilot study.  Once 
patients agreed to participate in the study and consent had been signed, there was random 
assignment of the subject, to either the comparison group or the treatment group through 
a random lottery selection process generated by a statistical analysis program.  If a patient 
requests for a particular group placement, he/she will be notified that participation can 
only by group randomization.  If the patient does not agree to the random group 
assignment, the patient will be informed that he/she will not be able to participate in the 
study.  The attending anesthesiologist and/or nurse anesthetist were the only staff that 
knew the assignment of the group placement.  The pre-operative and PACU nurses were 
blinded to the group placement to control bias in the scoring of PONV. 
 Sample attrition was expected to be nonexistent to minimal; since each subject 
had limited involvement in the study during their one visit at the ambulatory surgical 
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center.  This one-time encounter limited the opportunity for the subject to withdraw from 
the study.  By having this one-time encounter, the patient did not have any follow-ups 
with the researcher, which can sometimes be problematic and increase attrition rates by 
subjects not attending the follow-up (Grove et al., 2013).  The attrition rate for this study 
was zero. 
Research Strategies 
 To explore the research question, does the administration of sub-hypnotic doses of 
propofol, as an anti-emetic at extubation, affect post-operative nausea and vomiting 
(PONV) rates during the immediate post-operative period in adult female patients 
undergoing gynecologic laparoscopic procedures; a randomized, blinded, controlled 
comparison group study was completed.  This study was a pilot study to determine the 
feasibility and effectiveness of a larger study in the future. 
 Since there had not been a generation of point estimates, this intervention was to 
be conducted ans a pilot study.  Pilot studies are important in the generation of 
statistically significant randomized control trials because the feasibility and acceptability 
of the intervention are assessed, while also allowing alteration and improvement before 
implementation in a randomized control trial (Grove et al., 2013).  By generating data 
through implementation of the pilot study, adequate sample sizes can be determined 
through power calculation that can ensure that an appropriate number of subjects are used 
to determine statistical significance (Grove et al., 2013).  Since type II errors can result 
when the sample is inadequate, the pilot study will be used to support further research in 
this area if feasible; however, the results will not be generalized to the general population 
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because the population is non-representative and is often not a normal distribution (Grove 
et al., 2013). 
 The use of randomized control trials commonly occur when a convenience sample 
is used instead of randomized obtained sample pool (Grove, Burns, & Gray, 2013).  This 
type of study does have biases because of the convenience sample, but they also have 
internal validity because the two groups have similar variables that are crucial to the 
study (Grove et al., 2013).  The non-randomized sample does have external validity 
threats (Grove et al., 2013). 
 The random assignment to groups used to place subjects blindly in either a group 
that received only ZofranTM or a group who received ZofranTM and propofol.  The groups 
assignment remained unknown to the pre-operative and PACU nurses, but not to the 
anesthesia provider.  Since a comparison group is being used, the group that received 
ZofranTM only were used as a control group.  However, there were no ethical concerns 
since ZofranTM is the standard of treatment for PONV prevention; thus no medical 
treatment will be withheld.  Ondansetron is a selective serotonin (5-HT3) antagonist that 
is routinely used in anesthesia and throughout the medical field for nausea and vomiting 
prevention and treatment. 
Procedures 
 After obtaining IRB approval at the clinical site, Forrest General Hospital 
(Appendix D, E, & F) and The University of Southern Mississippi (Appendix G), the 
study was executed.  The initial step in the implementation process was providing 
education at the clinical site to the anesthesia providers, recovery room nurses, and pre-
operative nurses.  This education session provided information to the staff about the study 
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and how the implementation process would follow.  This step of obtaining buy-in from 
the clinical staff was a crucial goal to the success of the implementation phase of the 
study.   
 After education of the staff and clinicians about the pilot study, the actual 
implementation of the intervention was accomplished.  Patients, who consented to be in 
the study, were randomly assigned to either the control group or the treatment group 
blindly.  This process was accomplished by a random lottery, which assigned the patient 
a specific three character identifier.  The creation of these three character identifiers 
occurred using a random number generator.  This random creation of identifiers 
prevented any potential patterns recognizable by the recovery room nurses assessing 
PONV in the PACU.  Once the patient was assigned an identifier, there was a 
corresponding envelope placed with the patient’s anesthesia documents, and that 
remained sealed until in the operating room.  This envelope contained instructions to the 
anesthesia provider on what group the patient had been assigned.  The principal 
investigator collected and placed the patient’s demographic data on a pre-printed form.  
This form was used to analyze demographic data which will include: age, particular type 
of surgical procedure, race, height, weight, body mass index, smoking status and ASA 
classification (Appendix A).  This data will be retained securely as required by the 
University of Southern Mississippi and Forrest General Hospital IRB regulations.  As 
Forrest General Hospital has a longer requirement for record preservation, all documents 
will be kept for six years in a locked box in the principal investigator’s personal office.  
The documents will be available upon request by either IRB committee. 
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   The goal was that each group would have 20-25 subjects, which would have 
undergone random assignment to the group.  However, due to limitations of time due to a 
delay in IRB approval, there were a total of 10 subjects.  The subjects were randomly 
assigned to a group, with five subjects in each group. All subjects in the control group 
received ZofranTM (Ondansetron) at induction of anesthesia.  ZofranTM was administered 
at a dose of 0.1 mg/kg if less than 40 kg, and 4 mg if the weight was greater than 40 kg 
(Sharkey & Wallace, 2011).  All patients in the treatment group received ZofranTM at the 
same dose as the control group at induction of anesthesia, and also received 0.25 mg/kg 
of propofol at emergence with a max dose of 20 mg.  Ondansetron is a selective serotonin 
(5-HT3) antagonist that is routinely used in anesthesia and throughout the medical field 
for nausea and vomiting prevention and treatment.  By administering this to all patients, 
no care was withheld from the subjects. 
 In a study conducted by Borgeat et al., (1992), 10 mg of propofol was given and 
determined to be a sub-hypnotic dose.  To correctly account for weight, the avoidance of 
a blanketed dose allowed for consideration of a weight-based approach.  Thus, by 
administering 0.25mg/kg of propofol with a max dose of 20mg, appropriate doses could 
be given per weight.  Since the induction dose of propofol for anesthesia is 1-2 mg/kg, 
the dose of 0.25 mg/kg was well below the dose that would provide complete sedation 
(Nagelhout, 2014).  There is a decreased incidence of PONV with the administration of 
propofol for total intravenous anesthesia (TIVA) in patients with known history of PONV 
due to its antiemetic properties.  This TIVA approach requires a constant infusion of 
propofol during the case at high dosage levels of 100-200 mcg/kg/min to maintain 
general anesthesia.  The cost effectiveness of this anesthetic prevents its use in this 
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manner in all patients.  This study examined the use of small doses of propofol at the end 
(emergence) of surgery, which is less costly. 
 Propofol was prepared and labeled per protocol that included aseptic technique 
and placing the time of preparation on the syringe.  All propofol syringes were discarded 
after 6 hours and used for a single patient administration.  Should the anesthesia provider 
have determined that the propofol syringe was contaminated, they were instructed to 
discarded the syringe and prepare a new syringe of propofol.  If there were insufficient 
propofol left for the sub-hypnotic dose administration at the end of the anesthetic, the 
patient would have been removed from the study and a new vial would have not been 
charged. 
 All patients received a minimum 1 liter of normal saline or lactated ringer (LR) 
solution replacement using the 4-2-1 formula.  Pre-operative fluid management has been 
shown to prevent hypotension by avoiding vasodilation and to decrease the incidence of 
PONV by maintaining adequate systemic blood pressure (Lambert, Wakim, & Lambert, 
2009).  In a study conducted by Lambert et al. (2009), a lower incidence of PONV was 
observed in patients who received adequate and appropriate fluid replacement. 
  All patients received a standard intravenous induction of anesthesia with the 
combination of  0.07-0.15 mg/kg VersedTM, 1- 2.5 mg/kg Propofol,  1-1.5 mg/kg 
lidocaine, 2-50 mcg/kg fentanyl, 1-1.5 mg/kg Anectine, and 0.03 mg/kg ZemuronTM 
(Butterworth et al., 2013).  Appropriate doses were used for the induction of anesthesia 
based upon the patient’s body weight, physical assessment, and anesthesia provider’s 
preference.   
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 Maintenance of anesthesia was obtained by using a standardized concentration of 
a volatile agent and providing or maintaining normocapnic ventilation.  Desflurane 6.0%, 
sevoflurane 2.0 %, and isoflurane 1.2 % were the inhalational anesthetics used to 
maintain anesthesia (Butterworth et al., 2013).  While these levels are the minimum 
alveolar concentration (MAC) that is required to prevent movement in 50% of individuals 
to surgical stimulus, these levels were adjusted as necessary based upon the individual 
patient (Butterworth et al., 2013).  For the purpose of this project, the MAC of the 
volatile agent was maintained at 0.5-1.5% of MAC per the anesthesia provider’s 
discretion.  
 Maintenance of mean arterial pressure above 60 mmHg occurred during the 
procedure.  Mean arterial pressure is a calculated measurement using the systolic and 
diastolic blood pressure measurements to determine blood flow to important organs such 
as the brain and kidneys.  Administration of pain medication as needed to maintain 
comfort and hemodynamic.  Muscle relaxation was achieved as required by rocuronium 
0.3mg/kg, atracurium 0.2 mg/kg, or vecuronium 0.05 mg/kg for appropriate muscle 
paralysis as evident by decreased twitches to train of four (Butterworth et al., 2013).  The 
occurrence of fade, a gradual decline in response to nerve stimulation; or a complete loss 
of one or more of the four twitches elicited when using a nerve stimulator is supportive of 
a decrease nerve response (Butterworth et al., 2013).  This decrease in nerve response in 
anesthesia is due to blockade by a neuromuscular blocking drug.  The administration of 
these drugs is monitored by the train of four to determine patient’s readiness for 
emergence and ability to support one own breathing (Butterworth et al., 2013). 
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 Once the surgery was completed, the volatile agents were discontinued, and the 
treatment group received the assigned dose of propofol during emergence.  The definition 
of beginning of emergence for this project was the beginning of surgical closure.  
Appropriate muscle relaxant reversal was administered after evidence of return of at least 
one twitch in train of four (Butterworth et al., 2013).  Neostigmine 0.04-0.08 mg/kg and 
glycopyrrolate 0.2 mg/ml of neostigmine were used to reverse muscle relaxants 
previously administered (Butterworth et al., 2013).  Extubation of the patient occurred 
after the return of all four twitches without fade.  Fade is when the train of four ratio 
between twitches is less than 90% (Butterworth et al., 2013).  Fade means the fourth 
twitch is less than 90% strong as the first twitch.  After extubation, the patient was 
administered oxygen via a face mask. 
 After transferring the patient to the PACU, care of the patient was transferred to 
the PACU nurse at the discretion of the anesthesia provider.  Evaluation of the patients 
occurred by the PACU nurses, who were blinded to the group assignments.  The 
institution requires documentation of nausea and vomiting.  Thus, data was collected 
from the computerized charting and documented on the data collection form by the 
principal investigator.  See Appendix B for a scheduled timeline of this process and the 
initial goals of the study. 
 For the purpose of this study, the induction of anesthesia was defined as the time 
the patient receives the first injection of medication until the airway is secured either by 
using an endotracheal breathing tube or a laryngeal mask airway, which are breathing 
tube devices.  The securement of the airway was measured by end tidal carbon dioxide 
and equal bilateral breath sounds.  Maintenance of anesthesia began at airway securement 
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and continued until the beginning of emergence.  Emergence started at the beginning of 
surgical closure and continues until the patient was stable in the PACU. 
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CHAPTER IV 
ANALYSIS OF DATA 
Sample Demographics 
 A recruitment of a total of ten (N=10) subjects occurred for this project at the 
level II trauma center.  This sample was comprised completely of the female gender as 
required in the inclusion criteria.  The subjects were between the ages of 26 and 55, with 
a median of 36.5 (Table 2).  Sixty percent (n=6) of the participants were Caucasian, and 
40% (n=4) were African American (Figure 1).  All of the subjects (N=10) were classified 
as ASA 2 patients, meaning each had mild systemic disease.   
 The median height was 65.5 inches with all participants between 63 and 71 inches 
(Table 2).  The weights of the subjects were between 70 and 154 kilograms, with a 
median of 83.5 (Table 2).  By collecting the height and weight of the subjects, the BMI 
was able to be calculated.  The average BMI of the subjects was 33.87, with a minimum 
of 26.7 and a maximum of 53.4 (Table 2).  Ninety percent (n=9) were non-smokers, 
while 10% (n=1) smoked tobacco. 
Table 2 
Sample Demographics 
Total 
Subjects 
Item Mean Median Mode Std. 
Deviation 
Minimum Maximum 
N=10 Age 38.8 36.5 26 8.728 26 55 
N=10 Height 66.20 65.5 64 2.616 63 71 
N=10 BMI 33.87 30.25 30 8.019 26.7 53.4 
N=10 Weight 95.8 83.5 70 26.828 70 154 
 
Note.  Height is stated in inches.  Weight is stated in kilograms. 
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Figure 1.  Ethnicity. 
Procedure Demographics 
 Data collection of specific procedure information was collected to identify 
potential effects on PONV incidence.  Ninety percent (n=9) of patients had a laparoscopic 
assisted vaginal hysterectomy (LAVH), with 66.6% (n=6) of those undergoing bilateral 
salpingo-oophorectomy (BSO).  Ten percent (n=1) underwent an exploratory 
laparoscopic surgery with BSO. The mean anesthesia duration was 113.9 minutes, with a 
standard deviation of 29.77 minutes (Table 3).  The average estimated blood loss (EBL) 
was 240 milliliters (ml), with a minimum of 50 ml and maximum of 700ml (Table 3).  
The mean urine output (UOP) was 337.5 ml, with a minimum of zero and maximum of 
800 ml (Table 3).  The zero could be an error of omission by the anesthesia provider; 
however, this is unable to be proven and is considered an outlier.  The mean amount of 
fluids administered during anesthesia was 1492 ml with a standard deviation of 424.206 
ml (Table 3).  This study did not evaluate consideration of the type of fluid administered 
during surgery. 
 
Caucasian
African American
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Table 3 
Procedure Demographics 
Total Item Mean Median Mode Standard 
Deviation 
Minimum Maximum 
N=10 Time 113.9 101.5 99 29.377 92 170 
N=10 EBL 240 150 150 206.559 50 700 
N=10 UOP 337.5 275.0 0 284.129 0 800 
N=10 Fluids 1492 1550 700 424.206 700 2200 
N=10 PACU Time 57.9 58.5 60 9.303 42 72 
  
Note. Time = minutes.  EBL= ml.  UOP = ml. Fluids = ml.  PACU Time = minutes. 
Measurement Methodology 
 PONV severity was self-reported by the patient on a verbal analog scale of 0-10 
based on their experience.  The use of this assessment technique was a limitation of this 
study due to the documentation criteria that the clinical facility currently promotes.  
There was a possibility of some inter-reporter variability between patients due to the 
differences in experiences and views of the different levels of nausea.  Zero on the scale 
represented no nausea, while ten on the scale represented the worst nausea the patient has 
ever experienced.  Before being discharged from the PACU, patients underwent 
assessment for nausea.  However, if the patient experienced nausea or vomiting, a rescue 
anti-emetic was provided as ordered by the anesthesia provider.  The recovery room 
nurse documented the patient’s nausea score at the time of administration on the 
electronic medication record. 
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 The null hypothesis for this study was that there is no difference between the 
means of the control group, who will not receive propofol, and the treatment group, who 
will receive propofol at extubation.  The alternative hypothesis was that there will be a 
difference between means of the control group and the treatment group.  The level of 
significance that will be used will be 0.05, as this is the maximum level of alpha in 
scientific research (Houser, 2008).  
 A t-statistic was calculated from the data, and if lower than the predetermined 
alpha of 0.05, the null hypothesis will be rejected and the data will be determined as 
statistically significant (Houser, 2008).  The reported result, based on the collected data, 
includes the test statistic, the p-value, the mean difference between the two groups, and 
the confidence interval for the average difference.  This data will also allow for data 
points that could be used in further studies to determine adequate sample sizes to 
determine statistically significant data that would be generalizable. 
 Rating of vomiting occurred as a yes or no answer by the patient.  This vomiting 
data was used to formulate a chi-square test.  The chi-square test allowed the differences 
in proportion to being determined for vomiting between the two groups.  The assumption 
for the chi-square test is that only one data entry will be collected per patient; this was 
tracked and compared to the total number of participants. 
Statistical Analysis 
 After data collection occurred, a one-tail t-test was performed since only 
improvement in PONV was being assessed.  It is very unlikely that worsening of PONV 
by propofol since it has been demonstrated to have anti-emetic properties.  Also, since 
there were so many factors of PONV there is difficulty to isolate that propofol was the 
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culprit.  An independent t-test allowed the examination of the differences between the 
two different groups (Grove et al., 2013).  The use of the independent t-test normally 
involves the assumptions that the sample means from the population are of normal 
distribution, the dependent or outcome variable is measure at the interval/ration level, the 
two samples have equal variance, and the observations in each sample are independent 
(Grove et al., 2013).  However, since the t-test is robust, if an assumption has been 
violated the analysis can still be relied upon (Grove et al., 2013). 
 The data was entered into Statistical Package for Social Sciences (SPSS) 
statistical software.  A one-tail t-test was performed using a 95% confidence interval.  
This confidence interval defined the region of scores that is expected to include the true 
population mean (Aron, Aron, & Coups, 2008).  Thus, by setting a 95% confidence 
interval, there is a 95% chance the populations mean falls within this interval (Aron, 
Aron, & Coups, 2008).  
 After calculation of the statistical measurements, there was a noticeable difference 
in the standard deviations between the control (CX) and treatment (TX) groups (Table 4).  
The standard deviation of the TX group was 4.472, compared to that of the CX group of 
zero (Table 4).  To analyze the t-test, the Levene’s test for equality was used to determine 
if equal variances should be assumed or not assumed (Table 5). 
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Table 4 
Group Statistics 
Group N Mean Standard Deviation Std. Error Mean 
 
Nausea Score 
TX 5 2.00 4.472 2.000 
CX 5 0.00 0.000 0.000 
 
Note. TX= Treatment.  CX = Control. 
 When using Levene’s test for equality, the significance (p=0.029) is less than the 
stated level of p<0.05 (Table 5).  This determined that equal variances would not be 
assumed during the analysis of the t-test statistical data.  This decision was supported by 
the differences of standard deviation between the CX and TX groups. 
Table 5 
Levene’s Test 
 Levene’s Test for Equality t-test for Equality of Means 
Nausea 
score 
 F Significance T Df 
Equal variances 
not assumed 
 
7.111 
 
0.029 
1.000 8 
Equal Variances 
assumed 
1.000 4.000 
 
Note. DF = degrees freedom. 
 To determine if there is significance between the CX and TX means, the 
significance level between the CX and TX group was examined not assuming equal 
variances.  Since SPSS only calculates a two-tailed t-test, the significance data in the 
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table was corrected using the calculation to convert the significance level to represent that 
of a one-tailed t-test.  Since the significance level (p=0.174) is greater than the alpha level 
of 0.05, the null hypothesis is not rejected.  Thus, a paired samples t-test failed to reveal a 
statistically reliable difference between the mean of the CX (M = 0, SD = 0) and TX (M 
= 2.00, SD = 4.472) group created during this pilot study, t(8) = 1.000, p = .0.174, α = .05 
(Table 4 & Table 6). 
Table 6 
T-Test 
 t-test for Equality of Means 
Sig. Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
interval 
 
Nausea 
Score 
 Lower Upper 
Equal Variance 
assumed 
0.174 2.000 2.000 -2.612 6.612 
Equal variance 
not assumed 
0.174 2.000 2.000 -3.553 7.553 
 
Note. Sig. = Significance 
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Table 7 
Case Processing 
Cases 
 Valid Missing Total 
Nausea  
Score 
N Percent N Percent N Percent 
10 100.0% 0 0.0% 10 100.0% 
  
 Data analysis of the vomiting results was accomplished by the generation of a 
Chi-square analysis in SPSS.  A chi-square test was performed and no relationship was 
found between the CX and TX groups in relation to vomiting, X2 (1, N = 10) = 1.111, p 
=0.146 (Table 9).  To ensure accuracy of the Chi-square analysis, the case processing was 
analyzed for missing or repeated entries (Table 7).  The correct number of data entries 
were analyzed as evidenced by the total of ten (N=10) entries (Table 7 & Table 8). 
Table 8 
Symmetric Test 
  Value Approx. Sig. 
Nominal by 
Nominal 
Phi 0.333 0.292 
 Cramer’s V 0.333 0.292 
Number of Valid Cases 10  
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Table 9 
Nausea Score Cross-tabulation 
 Nausea Score Total 
0 10 
Group CX Count 5 0 5 
% within group 100.0% 0.0% 100.0% 
% within nausea score 55.6% 0.0% 50.0% 
% of Total 50.0% 0.0% 50.0% 
TX Count 4 1 5 
% within group 80.0% 20.0% 100.0% 
% within nausea score 44.4% 100.0% 50.0% 
% of Total 40.0% 10.0% 50.0% 
Total  Count 9 1 10 
 % within group 90.0% 10.0% 100.0% 
 % total 90.0% 10.0% 100.0% 
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Table 10 
Chi-Square Tests 
 Value Df Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. (1 
sided) 
Pearson Chi-Square 1.111 1 0.292   
Continuity Correction 0.000 1 1.000   
Likelihood Ration 1.498 1 0.221   
Fisher 
S Exact Test 
   1.000 0.500 
N of Valid Cases 10     
 
 Since this table is a 2x2, the Phi measure of association will be analyzed instead 
of Cramer’s V (Table 10).  The level of association that Phi represents is 0.333 level of 
association between vomiting and the use of propofol as an anti-emetic.  
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CHAPTER V 
SUMMARY 
Significance and Implications 
 The results of this pilot study did not show a statistical significance for the 
administration of the sub-hypnotic doses of propofol in the prevention of PONV.  The 
only patient who experienced PONV in either of the two groups was in the group which 
received propofol.  There were other possible contributing factors that caused the PONV 
such as the patient received an oral medication prior to the induction of anesthesia.  Thus, 
this could have increased the risk of PONV in this specific patient.  The current evidence 
still supports that propofol as having anti-emetic properties, thus, the limitations of this 
study must be accounted for, and the study possibly repeated on a more extensive scale. 
  During a future study, a larger randomized control study could be performed in 
other patient populations and surgical procedures to obtain a statistically significant 
outcome.  Clinical anesthesia providers attempt to prevent PONV by medications that are 
available on the market, however, between anesthesia providers there is little consistency 
and evidence for support of the regimens being administered.  If sub-hypnotic propofol 
proves statistically significant in preventing PONV in the future, the evidence will 
support the dose and timing of the administration of propofol to prevent PONV. 
Limitations 
 There were several limitations encountered during this study.  The largest 
limitation was the lengthy IRB approval process and the limited time frame for the 
completion of the project.  Due to the limited time frame, a small number of subjects 
were recruited, and the total goal of participants did not occur. 
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 Due to the limited number of subjects used for this pilot study, the results are 
limited in their use of determining the effectiveness of the intervention.  However, the 
implementation of the intervention allowed the discovery of limitations that need to be 
accounted for if a larger study was conducted.  There needs to be sufficient time for 
implementation of the study.  However, the implementation process would be more 
efficient of the principal investigator was employed by the hosting facility. 
 Another limitation encountered was the recruitment of subjects and providers.  
There was minimal rejection by the patients that were approached, however, the 
scheduling of the surgeries made the recruitment difficult.  The surgeries were scheduled 
with large lapses of time between the surgeries, making the process inefficient.  Also, if 
the same group of providers could be used the results would be more reliable and 
consistent due to continuity.  All of these are limitations that require consideration in 
future studies. 
DNP Essentials 
 The eight foundational DNP essentials were obtained while implementing this 
pilot study.  Essential I: Scientific underpinning for practice was achieved by performing 
a complete literature review to formulate an evidenced-based practice plan to decrease 
PONV by administering sub-hypnotic doses of propofol.  This allowed a current practice 
issue to be addressed using the latest research available.  Essential II: Organizational and 
systems leadership for quality improvement and systems thinking was obtained by 
collaborating with institutional leadership to provide an intervention to improve quality 
of care while still considering financial obligations of the institution to provide low cost 
high quality care.  This was accomplished by ensuring that there was no increase in work 
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on the surgical staff and that there were no increased in costs due to the need of 
additional pharmaceuticals for the intervention.   
 Essential III: Clinical scholarship and analytical methods for evidenced-based 
practice was achieved by performing a literature review of relevant research using 
electronic databases to formulate the clinical improvement intervention.  Clinical 
scholarship was continued by the writing and copyright of this nursing capstone 
document which helps to disseminate the findings of this intervention.  Essential IV:  
Information systems/technology and patient care technology for the improvement and 
transformation of health care was met by using the electronic medical record for data 
collection.  The latest trend in healthcare is to use electronic medical records to improve 
patient care, however, it allows much quicker and efficient data extraction from medical 
records than previous paper documents.  The data for the project was extracted by the 
principal investigator from the electronic medical record. 
 Essential V: Health care policy for advocacy in health care was obtained by 
influencing committee members and institutional leadership to allow the implementation 
of the intervention to decrease PONV.  During this process, education was able to be 
provided to these individuals about the role of the advanced practice nurse not only in the 
clinical realm, but also in improvement of health care outcomes by scholarly activities.  
Essential VI: Inter-professional collaboration for improving patient and population health 
outcomes was met by being a leader in the clinical implementation of the clinical 
intervention.  The principal investigator served as the front line leadership with pre-
operative and PACU nurses, in addition to the anesthesia providers.  The investigator 
coordinated the care required for participants enrolled in the study.  Essential VII: 
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Clinical prevention and population health for improving the nation’s health was achieved 
by analyzing statistical and scientific data during the needs assessment to determine the 
need and feasibility of using propofol as a preventative method against PONV.  Essential 
VIII: Advance Practice was obtained by establishing therapeutic relationships with the 
subjects to improve patient outcomes.  This was achieved by developing and 
implementing the therapeutic intervention. 
Future Directions 
 Further research needs to be completed to determine the effectiveness of sub-
hypnotic doses of propofol at emergency in preventing PONV.  A larger sample cohort 
needs to be recruited, with a potential for including other high-risk surgical procedure 
types in the future studies.  Future studies should plan ample implementation time and 
consider using a select group of anesthesia providers to produce consistency in the study.  
However, the most important part is to disseminate findings of these types of studies.  If 
dissemination is not performed, clinical practice change is unable to be implemented by 
clinicians to improve patient outcomes on a national and international level. 
Conclusion 
 The incidence of PONV remains a concern to practicing anesthesia clinicians.  
While the statistical data of this pilot study is not overwhelmingly support of the use of 
propofol as an anti-emetic in sub-hypnotic doses, this pilot study was limited.  Further 
research needs to be continued with this intervention, after addressing the limitations of 
this study, to determine its potential effectiveness of the use of sub-hypnotic doses of 
propofol in preventing PONV.  The incidence of PONV still requires further research to 
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determine prevention measures to improve patient outcomes and provide high quality lost 
cost health care patients to future surgical patients. 
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APPENDIX A 
DATA COLLECTION FORM 
Participant ID #:_______________ Procedure date:_______________ 
Age:_______________  
Procedure:_______________  
Start time:__________  End 
time:__________ 
Total anesthesia time:_______________ 
Height:_______________  
Weight:_______________ BMI:_______________ 
ASA:_______________  
  
Smoker or Non-Smoker  
  
Caucasian,  African American, Hispanic,  Other:_________________ 
 
Induction 
Drug Dose 
  
  
  
  
 
Maintenance 
Drug Dose 
  
  
  
  
 
Emergence 
Drug Dose 
  
  
PACU  Arrive:_________________  Discharge:______________________ 
Total amount of fluids:__________________________ PONV score:___________ 
EBL:____________________    UOP:______________    Nausea: Yes or No   
Rescue Anti-emetic:__________________________ 
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APPENDIX B 
PROJECTED TIMETABLE 
 
  
Event Date 
Research proposal approval September 15, 2014 
IRB Submission September 30, 2014 
IRB approval October 31, 2014 
Clinical site education sessions November 30, 2014 
Intervention Implementation December 1, 2014 
Data Collection Completion May 15, 2015 
Rough Draft of final document July 15, 2015 
Oral Defense of Capstone September 1, 2015 
Submit hard copy of project to Graduate 
reader for proofing 
September 2015 
Submit final copy to Graduate reader October 2015 
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APPENDIX C 
LOGIC MODEL 
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APPENDIX D 
FORREST GENERAL IRB APPROVAL 
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APPENDIX E 
FORREST GENERAL REVISION APPROVAL 
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APPENDIX F 
FORREST GENERAL CONTINUE APPROVAL 
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APPENDIX G 
UNIVERSITY IRB APPROVAL 
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APPENDIX H 
LETTER OF SUPPORT 
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APPENDIX I 
RESEARCH PROTOCOL 
RESEARCH PROTOCOL  
TITLE: A Pilot Study of Propofol as an Anti-emetic in laparoscopic, 
gynecologic surgery patients. 
INVESTIGATORS: Flem-Flam Flemister, SRNA, BSN 
         Vickie Stuart, CRNA, DNP 
RESEARCH PLAN 
A. Clinical Question 
  How does the administration of a sub-hypnotic dose of propofol, as an 
anti-emetic administered during emergence, affect PONV rates in females 
undergoing gynecologic, laparoscopic surgery? 
B. Background and Significance  
While PONV has been recognized as a common complication of 
anesthesia for many decades, it remains a major problem of anesthesia practice in 
the clinical setting today (DeLeskey, 2009; Hambridge, 2012; Thompson, 1999).  
Among patients that have multiple risk factors, or are considered high-risk 
patients, PONV incidence can be as high as 70% (Deleskey, 2009; Hambridge, 
2012).  Abdominal laparoscopic procedures have a higher incidence of PONV due 
to insufflation of the abdomen and bowel manipulation (Butterworth et al., 2013; 
Joshi & Cunnignham, 2013; Pawar, Sarkar, & Dewoolkar, 2009).  Thus, 
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laparoscopic gynecologic surgical patients were identified as a high-risk patient 
population for PONV and the recommendation is that a multimodal antiemetic 
approach be implemented in this population (Joshi & Cunnignham, 2013).  
  Propofol has been noted to decrease PONV among patients who receive it. 
The studies conducted by Borgeat et al. (1992) and Gan et al. (1996), both support 
the antiemetic properties of propofol and its use in anesthesia management. While 
propofol is known to have antiemetic properties, the site of action is still unknown 
(Borgeat et al., 1992; Gan, Ginsberg, Grant, & Glass, 1996; Gan et al., 1997). 
C. Inclusion Criteria 
 Female 
 Gynecologic surgery 
 Laparoscopic surgery 
 No history of PONV 
 American Anesthesiologist Association (ASA) Physical Status (PS) 1 or 2 
 Age 18-65 
. 
E. Exclusion Criteria 
 Ages less than 18 and greater than 65 
 History of PONV 
 Diabetes 
 Known allergies to soy or egg products 
 Systolic blood pressure less than 90 mmHG 
 Allergy to sulfites 
 Hiatal hernia 
 Gastroparesis 
 Non-English speaking 
 Pregnant 
 Currently  
F. Methods 
 Potential candidates for participation will be identified and approached by 
the principal investigator.  Study participation will be explained to patient 
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and informed consent obtained.  Consent will also be obtained from the 
assigned anesthesia provider to the case. 
 Patient will be assigned a unique identifier for the purpose of the study to 
protect health information.  This random identifier will be randomly pre-
assigned a designation of control group or intervention group.  This 
information will be provided to the anesthesia provider via a sealed 
envelope. 
 All subjects in the control group will receive Zofran at induction of 
anesthesia.  Zofran will be given at a dose of 0.1 mg/kg if less than 40 kg, 
and 4 mg if greater than 40 kg (Sharkey & Wallace, 2011).  All patients in 
the treatment group will receive Zofran at the same dose as the control group 
at induction of anesthesia, and also received 0.25 mg/kg of propofol at 
emergence with a max dose of 20 mg. 
 All patients will receive at minimum 1 liter of normal saline replacement 
using the 4-2-1 formula. 
 All patients will receive a standard intravenous induction of anesthesia with 
the combination of  0.07-0.15 mg/kg versed, 1- 2.5 mg/kg Propofol,  1-1.5 
mg/kg lidocaine, 2-50 mcg/kg fentanyl, 1-1.5 mg/kg Anectine, and 0.03 
mg/kg Zemuron (Butterworth et al., 2013). Appropriate doses will be used 
for the induction of anesthesia based upon the patient’s body weight and 
physical assessment.   
 Maintenance will be performed using a standardized concentration of 
volatile agent and normocapnic ventilation will be provided or maintained.  
Desflurane 6.0%, Sevoflurane 2.0 %, and Isoflurane 1.2 % will be the 
inhalational anesthetics used to maintain anesthesia (Butterworth et al., 
2013).  While these levels are the minimum alveolar concentration (MAC) 
that is required to prevent movement in 50% of individuals to surgical 
stimulus, these levels will be adjusted as necessary (Butterworth et al., 
2013).   Mean arterial pressure will be maintained above 60 mmHg.  Pain 
medication will be provided as needed to maintain comfort and 
hemodynamic.  Muscle relaxation will be used a required by rocuronium 
0.3mg/kg, atracurium 0.2 mg/kg, or vecuronium 0.05 mg/kg for appropriate 
muscle paralysis as evident by decreased twitches to train of four 
(Butterworth et al., 2013). 
 Once the surgery is completed, the volatile agents will be discontinued and 
the treatment group will receive the assigned dose of propofol immediately 
before extubation.   Appropriate muscle relaxant reversal will be given after 
evidence of return of at least one twitch in train of four (Butterworth et al., 
2013).  Neostigmine 0.04-0.08 mg/kg and glycopyrrolate 0.2 mg/ml of 
neostigmine will be used to reverse muscle relaxants (Butterworth et al., 
2013). 
 After emergence, the patient will be transported to the PACU by the 
anesthesia provider.  Care will be transferred to the PACU nurse once the 
anesthesia provider deems appropriate.  Patients will be assessed for PONV 
by the PACU RN, which will be blinded to the group assignments.  
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Documentation of nausea and vomiting are required by the institution, thus 
data will be collected from the computerized charting.  If a patient in either 
group experiences PONV, treatment will be provided per the anesthesia 
provider’s post-operative orders.  Common post-operative PONV treatment 
is intravenous ondansetron 0.1mg/kg if less than 40 kg or 4 mg if greater 
than 40 kg, or Phenergan intravenous 6.25 to 12.5 mg.  The PONV data will 
then be collected from the electronic health record by the primary 
investigator. 
K. Costs To Subjects: 
 There will be no additional costs to the patient because there are often small 
amounts of propofol left over from induction for use at emergence.   
L. Subject Compensation:  
Subjects and providers will not be compensated for their consent to participate in 
the study. 
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